Extended follow-up of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial indicated no mortality benefit from screening for ovarian cancer with annual CA125 and transvaginal ultrasound [178]. This evidence concerns the gene MUC16 and ovarian cancer.